The new science of hair restoration

01What has actually changed

For a long time the options for male pattern hair loss were a short list: two medicines, a surgical procedure, or acceptance. That list has not been replaced, but it has been surrounded. Clinics now offer a group of treatments described as regenerative, aimed at influencing the follicular environment rather than at blocking an androgen pathway.

Some of this is genuine research activity, and the underlying science of follicular signalling is a real field. Some of it is a marketing category assembled around a word. Separating the two is difficult from outside, and the difficulty is the reason this article exists.

02The baseline that has not changed

Male pattern hair loss remains an androgen driven, genetically influenced condition in which susceptible follicles progressively miniaturise. It is progressive, which means any intervention is applied against ongoing change, and it responds better to earlier intervention than to later.

The treatments with the strongest evidence remain licensed medicines regulated by the MHRA, one of which is prescription only in the UK and requires a discussion of side effects. Both require continuous use, and benefit is lost on stopping. Anyone considering the newer options should have established a position on the older ones first, because they are the comparator. That ground is covered in what is evidenced and what is sold.

03The regenerative category, described carefully

Regenerative is doing a great deal of work as a term. It covers approaches that differ substantially from each other in what is administered, how it is prepared, how it is delivered and what evidence exists. Grouping them makes them look like one field with one evidence base, which they are not.

The responsible description is that the published human research differs by approach, that several are small, short or produced by parties with an interest in the outcome, and that a plausible biological rationale is present in most cases while demonstrated benefit at the level a patient would notice is present in fewer. That is a considerably duller statement than the marketing, and it is what can be said accurately.

04The regulatory distinction that matters

A licensed medicine has been assessed for a specific indication, which means a regulator has looked at evidence of efficacy and safety for that use. A clinic delivered procedure that has not been through that route has not had the same scrutiny for that indication, whatever the quality of the underlying research.

This is why the wording used in advertising is informative. Where a treatment is described in terms of supporting scalp health, improving density or optimising the follicular environment rather than treating hair loss, the wording is being chosen to stay on the correct side of a regulatory boundary. Reading the claim type tells you what a provider believes can be substantiated, a point made generally in phrases with no fixed meaning.

05Questions to put to a clinic

1. What exactly is being administered, and how is it prepared?
2. What published human evidence supports this specific approach, rather than the category?
3. What outcome measure was used, and over what period?
4. How does this compare with licensed treatment, and should I be on that as well?
5. What happens when I stop?
6. Who is delivering it, what are they registered with, and what is the complication plan?

The fifth question is the one most often left unasked and most often decisive, because a treatment requiring indefinite repetition is a different financial and practical proposition from one that is completed.

06Diagnosis first, always

Not all hair loss is androgenetic, and this is where a treatment led approach does real harm. Alopecia areata produces well demarcated patches and is autoimmune. Telogen effluvium produces diffuse shedding some months after illness, surgery, significant weight loss or severe stress, and frequently resolves. Scarring alopecias destroy follicles permanently and are urgent. Thyroid disease and iron deficiency can contribute.

A course of any treatment purchased without establishing which of these applies is a course of treatment purchased blind. Sudden loss, patchy loss, loss with scaling, redness, pain or scarring warrants a GP appointment before anything else, and the NHS publishes clear guidance on what to look for.

07What separates practices in this area

The clinics worth taking seriously in regenerative hair work tend to share observable characteristics: they diagnose before proposing, they discuss licensed medical treatment rather than positioning themselves as an alternative to it, they describe evidence with its limitations attached, they set expectations in terms of density and maintenance rather than restoration, and they explain what happens on stopping.

Among London practices working in this area, Mesglo London in Marylebone positions itself around regenerative protocols with assessment first, which is offered here as an illustration of the model rather than as a recommendation. We have not assessed its clinical practice. The questions above should be put to any provider, and a practice that answers them plainly is telling you more than any before and after gallery.

08Where surgery fits

Transplantation moves follicles from an area less affected by androgen sensitivity to one that is. It does not create new follicles, so the donor area is finite and every procedure spends part of it. That single fact determines most of the good advice in the field.

It follows that surgery performed early, without medical treatment to slow ongoing loss, risks producing a transplanted region that separates from receding native hair over subsequent years. Planning for the pattern at sixty rather than at thirty is what distinguishes careful practice, and overseas surgery raises additional questions about who manages complications and follow up after the return flight.

09Expectations, set properly

• Evidenced treatments slow loss and produce partial improvement. They do not restore a hairline from a decade ago.
• Earlier intervention outperforms later intervention across essentially every option.
• Most treatments in this field require continuous use or repetition, and benefit is lost on stopping.
• Regenerative approaches vary; assess the specific approach rather than the category.
• Anything sudden, patchy, painful or scarring is a GP question first.

10The consumption angle

This publication looks at men's grooming through formulation and consumption, and hair restoration is the category where that lens is most useful, because it is the category with the most subscription selling, the most bundling and the highest rate of purchases made under urgency.

Urgency is the mechanism. A progressive, visible, emotionally significant change with a treatment window that narrows produces exactly the conditions in which people buy things they would otherwise assess. The corrective is to separate the medical question, which has a small number of evidenced answers and belongs with a prescriber, from the purchasing question, which can wait a fortnight without consequence.